most evidence is preclinical and observational
This so that people can make their own choice about how they will research the peptide
The patient has realistic expectations: modest additional fat loss over a defined cycle, not a return to early-phase GLP-1 weight loss rates
This decline correlates with reduced tissue repair capacity, increased systemic inflammation, and the progressive cellular dysfunction we associate with biological aging
Retatrutide is a triple agonist acting on GLP-1, GIP, and glucagon receptors, with phase 2 data published in the New England Journal of Medicine (2023) showing substantial weight reduction
During Adrenal Fatigue, your body can become very sensitive to products which include supplemental glutathione and NAC